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Retrospective Analysis of 
Radiological Recurrence Patterns 
in Glioblastoma, Their Prognostic 
Value And Association to 
Postoperative Infarct Volume
Stefanie Bette1, Melanie Barz2, Thomas Huber3, Christoph Straube4,7,8, Friederike Schmidt-Graf5, 
Stephanie E. Combs4,7,8, Claire Delbridge6, Julia Gerhardt2, Claus Zimmer1, Bernhard Meyer2,  
Jan S. Kirschke  1, Tobias Boeckh-Behrens1, Benedikt Wiestler1 & Jens Gempt2
Recent studies suggested that postoperative hypoxia might trigger invasive tumor growth, resulting 
in diffuse/multifocal recurrence patterns. Aim of this study was to analyze distinct recurrence patterns 
and their association to postoperative infarct volume and outcome. 526 consecutive glioblastoma 
patients were analyzed, of which 129 met our inclusion criteria: initial tumor diagnosis, surgery, 
postoperative diffusion-weighted imaging and tumor recurrence during follow-up. Distinct patterns of 
contrast-enhancement at initial diagnosis and at first tumor recurrence (multifocal growth/progression, 
contact to dura/ventricle, ependymal spread, local/distant recurrence) were recorded by two blinded 
neuroradiologists. The association of radiological patterns to survival and postoperative infarct volume 
was analyzed by uni-/multivariate survival analyses and binary logistic regression analysis. With 
increasing postoperative infarct volume, patients were significantly more likely to develop multifocal 
recurrence, recurrence with contact to ventricle and contact to dura. Patients with multifocal recurrence 
(Hazard Ratio (HR) 1.99, P = 0.010) had significantly shorter OS, patients with recurrent tumor with 
contact to ventricle (HR 1.85, P = 0.036), ependymal spread (HR 2.97, P = 0.004) and distant recurrence 
(HR 1.75, P = 0.019) significantly shorter post-progression survival in multivariate analyses including 
well-established prognostic factors like age, Karnofsky Performance Score (KPS), therapy, extent 
of resection and patterns of primary tumors. Postoperative infarct volume might initiate hypoxia-
mediated aggressive tumor growth resulting in multifocal and diffuse recurrence patterns and impaired 
survival.
Glioblastoma (GB) is the most common malignant brain tumor of adults. Despite aggressive therapy includ-
ing surgery and combined radiochemotherapy according to the Stupp protocol almost all patients show early 
recurrence and fatal outcome1,2. Several prognostic factors have been established, including age, Karnofsky 
Performance Score (KPS), extent of resection and molecular markers3–8. Studies showed that postoperative 
infarct volume is - beside its impact on postoperative functional independence - also an independent prognostic 
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factor for overall survival9–11. A recent study demonstrated that patients with ischemia after glioblastoma surgery 
are more likely to develop diffuse and more distant tumor recurrence, suggesting that postoperative hypoxia 
might introduce an infiltrative tumor growth with distinct recurrence patterns12. In fact, most GB show local 
tumor recurrence, with only about 10% having distant tumor growth at first recurrence13,14. However, distant 
tumor recurrence and tumor recurrence close to the ventricle are known to be associated with impaired overall 
survival15–17.
The authors hypothesize (i) that there might be correlations between postoperative infarct volume and recur-
rence patterns and (ii) that these radiological recurrence patterns are associated with patients’ prognosis (overall 
survival (OS) and post-progression survival (PPS)).
Patients and Methods
Ethical approval was obtained by the local ethics committee for this retrospective, non-interventional retrospec-
tive single-center study. Informed consent was waived by the local ethics committee due to the retrospective 
design of this non-interventional study. The study was conducted in accordance with the ethical standards of the 
1964 Declaration of Helsinki and its later amendments18.
Patient population. 526 consecutive glioblastoma patients treated in our institution between January 2006 
and March 2016 were retrospectively analyzed. 251 patients have been previously reported. This prior article dealt 
with the impact of postoperative infarct volume on overall survival9. From this previous cohort 129 patients met 
our inclusion criteria: surgery (biopsies were excluded) for a newly diagnosed glioblastoma (WHO IV) without 
previous treatment (eg surgery or radiochemotherapy for a lower grade glioma), early postoperative MRI (<72 h) 
including postoperative diffusion weighted imaging (DWI) and tumor recurrence (with available MRI) during 
the observation period. Exclusion criteria comprised previous treatment of the glioma/glioblastoma, missing 
postoperative diffusion weighted imaging or missing tumor recurrence.
Patients’ medical charts were analyzed for the following parameters by a neurosurgeon, blinded to radiological 
recurrence patterns: pre- and postoperative KPS, KPS at date of recurrent disease (postoperative KPS in case of 
second surgery), neurological status after initial surgery, date of surgery, 5-aminolevulinic acid (5-ALA)/intraop-
erative neuromonitoring (available in 128/129 patients), date of death or date of last contact in alive patients. Date 
of tumor progression was defined as date of MRI with progressive disease according to the RANO criteria19 and 
in an interdisciplinary consensus of neurosurgery, neuroradiology, radiation oncology, neuropathology, nuclear 
medicine and neurooncology. OS and progression free survival (PFS) were calculated from the date of surgery. 
PPS was calculated from date of tumor recurrence (MRI) to death/last contact. Treatment regimens after initial 
surgery/tumor diagnosis as well as after tumor recurrence were recorded for each patient.
Histopathological analysis was performed according to the WHO criteria of CNS tumors20.
Methylation status of O6-methylguanine DNA methyltransferase (MGMT) was analyzed quantitatively (per-
centage) and available in 95/129 cases. Proliferation index Ki67 was calculated by the ratio of labeled to unlabe-
led nuclei (percentage) (MIB-1 antibody, anti-Ki-67, 1:50, Dako, Hamburg, Germany) and available in 60/129 
patients.
Magnetic resonance imaging. Early postoperative MRI scans were performed in the Department of 
Neuroradiology at a 3 Tesla MRI scanner, either Philips Achieva or Philips Ingenia (Philips Medical Systems, The 
Netherlands B.V.) or Siemens Verio (Siemens Healthcare, Erlangen, Germany). Postoperative images included 
DWI or Diffusion Tensor Imaging (DTI), from which apparent diffusion coefficient (ADC) maps were calculated 
automatically (Achieva: DWI: 2:10 min, 7221/55 ms, 2 × 2 × 2 mm; DTI: 6.26 min, 10728/55 ms, 2 × 2 × 2 mm; 
Ingenia: DTI: 4.58 min, 16119/61 ms, 2 × 2.04 × 2 mm; Verio: DWI: 2:30 min, 5700/91 ms, 1.4 × 1.4 × 4 mm, 
DTI: 1:28 min, 3600/95 ms, 1.8 × 1.8 × 4 mm). Postoperative images as well as preoperative and follow-up 
images also included T2-weighted fluid attenuated inversion recovery (FLAIR) images (Achieva: 2D FLAIR: 
3:00 min, TR/TE: 12000/140 ms, spatial resolution 0.45 × 0.45 × 4 mm; 3D FLAIR: 4:52 min, 4800/278 ms, 
1.04 × 1.04 × 1.12 mm; Ingenia: 2D FLAIR: 3:00 min, 12000/140 ms, 0.9 × 0.95 × 4 mm, 3D FLAIR: 4:34 min; 
4800/302 ms, 1.12 × 1.12 × 1.12 mm; Verio: 2D FLAIR: 3:44 min, 8560/136 ms, 0.8 × 0.4 × 4 mm, 3D FLAIR: 
5:52 min, 5000/395 ms, 1 × 1 × 1 mm) and T1w with and without contrast agent (Achieva: 2D T1: 2:53 min, 
530/10 ms, 0.45 × 0.45 × 4 mm; 3D T1: 5:55 min, 9/4 ms, 1 × 1 × 1 mm, Ingenia: 2D T1: 3:16 min, 590/10 ms, 
0.9 × 1.12 × 4 mm; 3D T1: 5:59 min, 0.99 × 1.05 × 1 mm, Verio: 2D T1: 4:02 min, 2000/9 ms, 0.9 × 0.7 × 4 mm; 3D 
T1: 4:18 min, 1900/2.45 ms, 1.1 × 1.1 × 1 mm). Magnograf® was administered intravenously (0.2 ml/kg, 0.5-1 ml/
sec), image acquisition started 90 seconds after administration of the contrast agent.
Image analysis. Image analysis was performed by a neuroradiologist (SB, 6 years of experience) and a sec-
ond neuroradiologist (BW, 6 years of experience) for 60 randomly selected patients to assess interrater-reliability, 
blinded to patients’ outcome. Pre- and postoperative tumor volume (including the volume of the 
contrast-enhancing tumor part) was measured by manual segmentation using IPlannet (IPlan 3.0 cranial plan-
ning software, Brainlab AG, Munich, Germany) in T1-weighted images after contrast agent. Extent of resection 
was calculated by pre- and postoperative tumor volume and defined as complete resection (100%), near-total 
resection (>90%) and subtotal resection (<90%).
Manual segmentation was performed by a neuroradiologist (SB). To assess interrater-reliability, a second rater 
(MB, 2 years of experience) performed manual segmentation of pre- and postoperative tumor volume of 29 
patients (n = 58).
Postoperative ischemic lesions were also manually segmented by using IPlannet by a neuroradiologist (SB). 
Ischemia was defined as hyperintensity on b1000 images of DWI with a corresponding hypointensity on ADC 
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maps as described before9. Postoperative changes including edema and methaemoglobin were excluded from 
these volumes by fusion of T2-weighted FLAIR- and gradient-echo sequences to DWI images.
For primary tumors and tumor recurrence the following parameters were obtained:, uni- or multifocal (≥2 
enhancing lesions) recurrence, contact to dura, contact to the ventricle, ependymal tumor spread, haemorrhage. 
For contrast enhancement the following recurrence patterns were defined: invasive or displacing growth, homog-
enous or inhomogenous enhancement, with or without sharp demarcation, circular, garland-like, extensive, 
streaky or solid enhancement (Fig. 1). To simplify the analysis circular and garland-like contrast enhancement 
Figure 1. Examples of different radiologic recurrence patterns: (A) shows a multifocal, extensive tumor growth 
with contact to the ventricle, (B) a local, circular recurrence pattern, (C and D) an extensive multifocal, local 
and distant tumor growth with contact to ventricle and ependymal spread, (E and F) an extensive recurrence 
with contact to the ventricle.
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were summarized as well as extensive/streaky and solid enhancement. For tumor recurrence the location of recur-
rence was further recorded: local (with contact to the resection cavity) or distant (without contact) to the resec-
tion cavity.
The patterns of contrast enhancement were used for local and/or distant tumor recurrence.
Statistical analysis. Statistical analysis, including descriptive data analysis, was performed using IBM SPSS 
Statistics Version 23.0 (SPSS Inc., IBM Corp., Armonk, NY, USA). Non-normally distributed data are shown as 
median and interquartile range (IR), normally distributed variables as mean and standard deviation. Correlations 
between patterns of primary and recurrent tumors were analyzed using the Fisher’s exact test. Differences between 
two groups were analyzed by the Mann-Whitney U test. To assess relations between postoperative infarct volume 
and recurrence patterns a binary logistic regression model was performed for recurrence pattern as dependent 
variable and infarct volume as covariate (cm³). OS distributions were compared using Kaplan-Meier estimates 
(Log-rank) and a Cox proportional hazard regression model for multivariate survival analysis. For calculation 
of interrater-reliability for qualitative analysis the cohen’s kappa (standard error = ra) was used, for quantitative 
analysis the intraclass correlation coefficient (ICC). Differences with a type one error probability of less than 0.05 
were considered statistically significant.
Results
Patient population. 129 consecutive patients (52 female, mean age at initial diagnosis 59.4 years+/−12.8) 
who underwent surgery for a newly diagnosed glioblastoma (WHO IV) were retrospectively included in this 
single-center study (Table 1). The median preoperative KPS was 80 (IR 70-90), the median postoperative KPS 
was 80 (IR 70-90), the KPS at date of recurrent disease (postoperative KPS in case of second surgery) was 70 (IR 
60-80). 40/129 patients had temporary neurological deficits after surgery, 18 presented with permanent deficits. 
Histopathological analysis indicated MGMT promoter methylation in 36/95 cases. Median Ki67 was 20% (15–
25). 51/128 patients were operated using 5-ALA, 102/128 patients using intraoperative neuromonitoring. 94/129 
patients died during follow-up. Median overall survival was 16.1 months (95% CI 13.8–18.4) after initial diagno-
sis of a glioblastoma, median time to first tumor recurrence was 7.2 months (95% CI 5.6–8.8). Recurrent disease 
was proven histologically in 58/129 cases, by MR analysis according to the RANO criteria in 48/129 cases and 
by advanced imaging methods including O-(2-[18 F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography 
(FET-PET) or perfusion weighted imaging in 23/129 cases.
Almost all patients received adjuvant therapy after initial surgery (124/129), 106/129 patients received therapy 
for recurrent disease. After initial surgery, most patients (96/124) received combined radiochemotherapy accord-
ing to the Stupp protocol with six weeks of combined radiochemotherapy followed by six months of chemother-
apy with temozolomide2. At our department adjuvant therapy usually starts 2-4 weeks after surgery. Table 2 lists 
the therapy regimes after initial surgery and after diagnosis of recurrent disease.
The intraclass-correlation coefficient for volumetric measurement showed an excellent agreement between 
the two raters (0.988 [95% CI 0.979–0.993], p < 0.0001). Median preoperative tumor volume was 29.6 cm³ (IR 
11.7–54.0), median postoperative tumor volume 0.0 cm³ (IR 0.0-0.9). 65/129 patients had gross total tumor resec-
tion, 49/129 near-total tumor resection (>90%) and 15/129 subtotal tumor resection (<90%). No significant 
association was observed between the use of 5-aminolevulinic acid/intraoperative neuromonitoring and extent of 
resection/infarct volume. Postoperative ischemic changes were present in 113/129 patients including also rim-like 
infarctions surrounding the resection cavity. Median postoperative infarct volume was 2.0 cm³ (IR 0.8–5.3). 
Patients with insular tumors showed significantly larger infarct volumes (6.50 cm³ vs. 1.13 cm³; P = 0.040).
Age at date of initial diagnosis 59.4 y ( + /−12.8)
Sex, female 52/129 (40.3%)
KPS preoperative 80 (70–90)
KPS postoperative 80 (70–90)
KPS at recurrence 70 (60–80)
MGMT-methylation 36/95 (37.9%)
Ki67 20.0% (15.0–25.0)
Death during FU 94/129 (72.9%)
OS after ID 16.1 months (95% CI 13.8–18.4)
PFS 7.2 months (95% CI 5.6–8.8)
PPS 7.5 months (95% CI 6.4–8.6)
Preoperative tumor volume 29.6 cm³ (11.7–54.0)
Postoperative tumor volume 0.0 cm³ (0.0–0.9)
Postoperative infarct volume 2.0 cm³ (0.8–5.3)
Complete tumor resection 65/129 (50.4%)
Near-total tumor resection (>90%) 49/129 (38.0%)
Subtotal tumor resection (<90%) 15/129 (11.6%)
Table 1. Baseline patient and tumor characteristics. Normally distributed variables shown as mean + /− 
standard deviation, non-normally distributed as median (interquartile range); OS, overall survival, ID: initial 
diagnosis, PFS: progression free survival, PPS: post-progression survival.
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Primary tumors and recurrence patterns. Most of the primary tumors showed typical garland-like con-
trast enhancement (112/129) with invasive growth (121/129) and without sharp demarcation (116/129). Contact 
to the dura was observed in 73/129 patients, contact to ventricle in 62/129 patients (Table 3). 8/129 primary 
tumors were located in the insula.
Cohen’s kappa showed excellent agreement between the two readers for analysis of location of tumor recur-
rence (0.868, ra = 0.063, P < 0.001), multifocal tumor recurrence (0.836, ra = 0.079, P < 0.001), contact to dura 
(0.900, ra = 0.056, P < 0.001), contact to ventricle (0.928, ra = 0.050, P < 0.001), ependymal spread (1.000, 
ra = 0.000, P < 0.001), hemorrhage (1.000, ra = 0.000, P < 0.001), homogenous/inhomogenous enhancement 
(1.000, ra = 0.000, P < 0.001) and pattern of contrast enhancement (0.896, ra = 0.058, P < 0.001). Moderate agree-
ment was shown for the parameters invasive tumor growth (0.700, ra = 0.163, P < 0.001) and demarcation (0.632, 
ra = 0.115, P < 0.001).
Local tumor recurrence (at the site of former surgery) was observed in 72/129 patients. While 44 patients 
had a combined local and distant recurrence, we observed a sole distant tumor recurrence in 13 patients. 85/129 
patients presented with multifocal tumor recurrence, in 77/129 recurrent tumor mass had contact to the ven-
tricles. 64/129 patients showed tumor recurrence with contact to the dura, an ependymal tumor spread was 
observed in 14/129 patients. Almost all patients (128/129) had a contrast-enhancing tumor recurrence. The fol-
lowing contrast-enhancing patterns were observed: inhomogeneous in 98/128 patients, infiltrative in 124/129 
patients, without sharp demarcation in 105/129 patients and circular/garland-like in 59/128 patients. 5/129 
patients presented with hemorrhage at recurrent disease. Table 3 lists the recurrence patterns of all patients.
Significant correlations between primary and recurrent tumors were observed for the following parameters: 
contact to dura (P = 0.021), contact to ventricle (P < 0.01) and pattern of contrast enhancement (P = 0.017). No 
significant correlations were observed for multifocal growth (P = 0.106) and ependymal spread (P = 1.0).
Recurrence patterns and postoperative infarct volume. A binary logistic regression analysis revealed 
that with increasing postoperative infarct volume, patients were significantly more likely to develop multifocal 
tumor recurrence (OR 1.10 [95% CI 1.00–1.21] per cm³ ischemia volume, P = 0.040) as well as contact to ventricle 
(OR 1.14 [1.03–1.26], P = 0.012) and contact to dura (OR 1.07 [1.01–1.15], P = 0.029) (Fig. 2). No significant asso-
ciation was observed for location of tumor recurrence (OR 1.03 [0.98–1.09], P = 0.186), ependymal spread (OR 
1.01 [0.95–1.09], P = 0.726), pattern of contrast enhancement (OR 1.01 [0.96–1.06], P = 0.627), homogenous/inho-
mogeneous contrast enhancement (OR 1.05 [0.97–1.14], P = 0.210), invasive/displacing tumor growth (OR 1.04 
[0.87–1.24], P = 0.675) and demarcation (OR 1.02 [0.95–1.09], P = 0.627). Figure 3 shows examples of two patients.
Extent of resection did not show a significant correlation to infarct volume (Spearman: r = 0.078, P = 0.381). 
Further, binary logistic regression analysis did not show associations between extent of resection and aggressive 
recurrence patterns.
Overall survival. Univariate model. In univariate analysis the following parameters were significantly 
associated with survival: extent of resection (P < 0.001), postoperative KPS (<80/>/ = 80) (P = 0.027), KPS 
at tumor recurrence (P = 0.001), MGMT-methylation status (P = 0.013), adjuvant therapy after initial surgery 
(P = 0.003) and therapy for recurrent disease (P < 0.001). The following recurrence patterns were associated 
with impaired prognosis: multifocal tumor recurrence (P < 0.001), contact to ventricle (P = 0.002), ependymal 
spread (P = 0.019) and distant tumor recurrence (P = 0.012) (Fig. 4). Pattern of contrast enhancement (P = 0.132) 
and the presence of a new neurological deficit after surgery (temporary deficits: P = 0.733; permanent deficits 
P = 0.484) showed no significant association to patients’ prognosis. Multifocal growth and contact to ventricle for 
primary tumors missed statistical significance (P = 0.086/P = 0.059).
Multivariate model. The multivariate survival model included the following parameters: age at surgery, extent 
of resection, dichotomized KPS at tumor recurrence (<80/>/ = 80), therapy for tumor recurrence, multifocal 
growth and contact to ventricle of primary tumors, multifocal recurrence, contact to ventricle and ependymal 
spread at recurrence and location of tumor recurrence (distant/local). A significant impact on overall survival was 
present for extent of resection (<90% vs. >90%) (Hazard ratio (HR) 4.68 [95% confidence interval 2.42–9.02], 
Initial adjuvant therapy
- Stupp scheme 96/129 (74.4%)
- only chemotherapy 8/129 (6.2%)
- only radiotherapy 24/129 (18.6%)
- bevacizumab 4/129 (3.1%)
- Chlorethyl-Cyclohexyl-Nitroso-Urea (CCNU) 3/129 (2.3%)
Therapy after first recurrence
- surgery 56/129 (43.4%)
- chemotherapy 80/129 (62.0%)
- radiotherapy 47/129 (36.4%)
- bevacizumab 26/129 (20.2%)
- CCNU 13/129 (10.1%)
Table 2. Adjuvant therapy.
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P < 0.001), absence of further therapy for recurrent disease (HR 4.79 [2.46–9.35], P < 0.001) and multifocal 
tumor recurrence (HR 1.99 [1.18–3.34], P = 0.010) (Table 4).
Subgroup analysis of patients with available MGMT-methylation status only revealed the following significant 
parameters: extent of resection < 90% (HR 3.22 [1.54–6.76], P = 0.002) and no therapy for recurrent disease (HR 
4.21 [1.84–9.61], P = 0.001) and missing MGMT-methylation (HR 2.08 [1.07–4.03], P = 0.030. Multifocal tumor 
recurrence (HR 1.47 [0.75–2.86], P = 0.262) did not show statistical significance (Supplemental Table 1).
Progression free survival. Univariate model. In univariate survival analysis extent of resection and initial 
adjuvant therapy were the strongest parameter for PFS (P < 0.001). Primary tumors with contact to ventricle 
showed significantly impaired progression free survival (P = 0.048). Interestingly, patterns of recurrent tumors 
did not show a correlation to PFS in this univariate model.
Multivariate model. The multivariate survival model included the following parameters: age, extent of resec-
tion, postoperative KPS (<80/>/ = 80), initial adjuvant therapy, multifocal growth and contact to ventricle of 
primary tumors, multifocal recurrence, contact to ventricle and ependymal spread at recurrence and location of 
recurrence. Apart from the known prognostic factors like extent of resection and therapy, also multifocal tumor 
recurrence was shown to be a prognostic factor for PFS (HR 1.70 [1.10-2.63], P = 0.016) (Table 4).
Post-progression survival. Univariate model. For post-progression survival the following recurrence pat-
terns were significant prognostic factors: primary tumor with contact to ventricle (P = 0.048), location of tumor 
recurrence (P < 0.001), multifocal recurrence (P = 0.001), contact to ventricle (P < 0.001) and ependymal spread 
(P < 0.001) (Fig. 5).
Contact to dura (P = 0.582), homogenous/inhomogeneous (P = 0.686) and pattern of contrast enhancement 
(P = 0.384) of recurrent tumors were not shown as prognostic factors.
Primary tumor
Multifocal tumor 39/129 (30.2%)
Contact to ventricle 62/129 (48.1%)
Contact to dura 73/129 (56.6%)
Ependymal spread 0/129 (0%)
Hemorrhage 120/129 (93.0%)
Pattern of contrast enhancement
- circular/garland-like 112/129 (86.8%)
- extensive/solid/streaky 17/129 (13.2%)
- homogenous 121/128 (94.5%)
- inhomogenous 7/128 (5.5%)
with sharp demarcation 13/129 (10.1%)
without sharp demarcation 116/129 (89.9%)
invasive 121/129 (93.8%)
displacing 8/129 (6.2%)
Tumor recurrence
Location of recurrence
- local 72/129 (55.8%)
- distant 13/129 (10.1%)
- local and distant 44/129 (34.1%)
Multifocal recurrence 85/129 (65.9%)
Contact to ventricle 77/129 (59.7%)
Contact to dura 64/129 (49.6%)
Ependymal spread 14/129 (10.9%)
Hemorrhage 5/129 (3.9%)
Pattern of contrast enhancement (n = 128)
- circular/garland-like 59/128 (46.1%)
- extensive/solid/streaky 69/128 (53.9%)
- homogenous 30/128 (23.4%)
- inhomogenous 98/128 (76.6%)
with sharp demarcation 24/129 (18.6%)
without sharp demarcation 105/129 (81.4%)
invasive 124/129 (96.1%)
displacing 5/129 (3.9%)
Table 3. Patterns of primary tumors and tumor recurrence.
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Multivariate model. In the multivariate model contact to ventricle (HR 1.85 [1.04–3.28], P = 0.036), 
ependymal spread (HR 2.97 [1.41–6.26], P = 0.004) and location of recurrence (HR 1.75 [1.10–2.79], P = 0.019) 
remained as significant factors beneath the known variable therapy for recurrent disease (Table 4). Subgroup 
analysis of patients with available MGMT-methylation status showed similar results with contact to ventricle (HR 
2.83 [1.35–5.94], P = 0.006), ependymal spread (HR 4.44 [1.77–11.11], P = 0.001) and recurrence location (HR 
2.08 [1.22–3.55], P = 0.007) as significant factors (Supplemental Table 1).
Discussion
This study demonstrates that postoperative infarct volume after initial glioblastoma surgery is associated with dis-
tinct recurrence patterns, and that these recurrence patterns themselves are significantly associated with overall 
and post-progression survival.
Patterns of tumor recurrence have been well studied in the last decade13,14,21–23. Most studies evaluated four 
recurrence types according to the classification of Pope et al.: local, distant, diffuse, multifocal23. The predominant 
type is local tumor recurrence13,21,23–25. Whereas local tumor recurrence is associated with a better prognosis, the 
remaining recurrence patterns are associated with impaired overall survival15. Most studies focused on recurrence 
Figure 2. Boxplots for infarct volume and multifocal recurrence/contact to ventricle/contact to dura.
Figure 3. The first row (A–D) shows preoperative T1w contrast images (A), postoperative DWI (B) and 
T1w contrast images at date of tumor recurrence (C,D)). In the postoperative DWI only rim-like DWI-
hyperintensity without territorial ischemia was present, in this case a local unifocal recurrence pattern (C), but 
not multifocal recurrence with contact to ventricle (D) was observed. The second row (E–H) shows pre- (E), 
postoperative (F) and follow-up (G,H) images of another patient. (F) shows a larger DWI-hyperintensity in the 
territory of the anterior cerebral artery. In this case a multifocal tumor recurrence with contact to the ventricle 
was observed.
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patterns in correlation to specific therapy regimes, especially bevacizumab that was thought to be associated with 
a more invasive recurrence pattern and often FLAIR-only recurrence22–24,26.
In contrast to previous studies and the Pope criteria13,23 we analyzed only contrast-enhancing lesions, multifo-
cal was defined as >/ = 2 contrast-enhancing lesions (in contrast to at least 3 lesions (contrast-enhancing or not) 
of the Pope classification) and are therefore not in accordance with these recurrence patterns. In addition to these 
previously defined criteria by Pope et al.23, we however also analyzed the patterns of contrast enhancement, the 
demarcation of the lesion and the homogeneity of the tumor, aiming to better characterize different recurrence 
patterns. However, in this study we could not observe significant differences between different patterns of contrast 
enhancement.
Our results are in agreement with previous studies showing that overall survival as well as post-progression 
survival is reduced in patients with a more aggressive recurrence pattern, including multifocal growth, contact 
to the ventricle, ependymal spread and distant tumor recurrence12,15. However, there is limited knowledge about 
the biology of these aggressive recurrence patterns. A recent study highlighted that postoperative infarct volume 
is independently of postoperative KPS associated with reduced overall survival9. This raises the questions which 
biological mechanisms underlie impaired survival in these patients with larger postoperative infarctions. The 
present study discloses an association between large postoperative infarct volumes and multifocal tumor growth, 
recurrence with contact to the ventricle and contact to the dura. The first two patterns were independently asso-
ciated with impaired OS/PPS, which supports the hypothesis that postoperative ischemia triggers an aggressive 
growth pattern, leading to impaired survival. Although contact to the dura is not associated with impaired sur-
vival, this might also be a sign of tumor spread. Hypoxia is known to be a mediator for invasive tumor growth 
of glioblastoma27–29. Hypoxia-inducible factors (HIF), especially HIF1 and HIF2α are known to promote tumor 
growth and are therefore discussed as targets for therapy30,31. The results of our study confirm those of a previous 
study, which showed significantly more often diffuse/distant tumor recurrences in patients with postoperative 
infarctions12. These results suggest that reduction of postoperative infarct volume not only improves patients’ 
functional independence but also might reduce the risk of aggressive tumor growth and therefore impaired sur-
vival. One could assume that a more aggressive tumor resection might be the cause of larger infarct volumes and 
consequently diffuse tumor recurrence. However, in the present study extent of resection was not associated with 
aggressive tumor recurrence, suggesting that reduction of postoperative ischemia is of high importance32.
Another explanation might be that hypoxia has a negative effect on efficacy of radiotherapy. A recent study 
showed that initiating radiotherapy sooner than 24 days after surgery had a negative impact on overall survival 
and PFS, a finding that is also explainable by partial recovery of hypoxic areas after surgery33. Further studies that 
investigate the exact pathomechanisms that initiate this invasive, possibly hypoxia-mediated tumor growth will 
have to be performed to maybe reveal new therapy strategies.
Figure 4. Overall survival estimates (Kaplan-Meier) for different recurrence patterns.
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Recent investigations also focused on the subventricular zone that contains neural stem cells initiating inva-
sive tumor growth16,17,34. In this study we also observed significantly impaired survival for tumor growth at the 
ventricle and also a correlation between postoperative infarct volume and tumor recurrence with contact to the 
ventricle. Further studies might evaluate if there is also a correlation between these neural stem cells and hypoxia.
There are limitations of this study. The retrospective design is the main limitation of this study. This is also 
reflected by the different therapy regimes of the patients that were conducted at the discretion of the local expert 
committee and not in the framework of a study. Different therapy regimes and also the time frame between 
recurrence and therapy regimes might also affect radiological recurrence patterns. Especially bevacizumab is 
known to affect these patterns often showing a more diffuse tumor growth22. A recent study further did not show 
an association between recurrence patterns and survival in patients treated with bevacizumab35. However, in this 
study only 4/129 patients received bevacizumab before first tumor recurrence. The exact mechanisms and the 
influence of different therapy regimes on radiological recurrence patterns should be addressed in further studies.
Postoperative seizures are a common complication after glioma surgery. Post-ictal changes are known to show 
diffusion restriction on MR images. However, differentiation between post-ictal and ischemic changes are chal-
lenging, especially due to a high number of clinically hidden postoperative seizures.
Another bias might arise due to image analysis at different MRI scanners and therefore the use of different 
sequences.
Differentiation between tumor progression and pseudoprogression or contrast enhancement of postoperative 
ischemia are known to be a pitfall in radiological assessment of follow-up MRI36. Studies report that up to 20–30% 
of glioblastoma patients treated with radio- or chemotherapy present with pseudoprogression37. To address this 
bias in our study, the RANO criteria were used for radiological assessment, combined with advanced imaging 
methods (FET-PET, perfusion weighted imaging) and histopathological diagnosis of recurrence was obtained in 
almost half of the patient cohort.
Especially the measurement of small postoperative infarct volumes might introduce a bias, as differentiation 
between tumor recurrence and enhancing ischemia might be challenging. To account for this, we refer to the 
Parameter Hazard Ratio 95% CI P value
Overall survival
Age 1.01 0.99–1.03 0.411
Extent of resection (<90% vs. >90%)* 4.68 2.42–9.02 <0.001
No therapy for recurrent disease* 4.79 2.46–9.35 <0.001
KPS at recurrent disease (<80/>/=80) 1.29 0.77–2.14 0.334
Multifocal primary tumor 1.25 0.76–2.07 0.382
Primary tumor: contact to ventricle 0.98 0.57–1.70 0.948
Multifocal recurrence* 1.99 1.18–3.34 0.010
Recurrence: contact to ventricle 1.70 0.98–2.96 0.059
Ependymal spread 1.16 0.57–2.40 0.680
Recurrence location (distant vs. local) 1.27 0.78–2.06 0.333
Progression free survival
Age 1.01 1.00–1.03 0.155
Extent of resection (<90% vs. >90%)* 3.07 1.56–6.06 0.001
No initial therapy* 29.86 8.06–110.67 <0.001
Postoperative KPS (<80/>/=80) 1.21 0.80–1.82 0.374
Multifocal primary tumor 1.26 0.82–1.93 0.302
Primary tumor: contact to ventricle 0.92 0.58–1.46 0.716
Multifocal recurrence* 1.70 1.10–2.63 0.016
Recurrence: contact to ventricle 0.94 0.59–1.48 0.774
Ependymal spread 0.81 0.43–1.51 0.501
Recurrence location (distant vs. local) 0.87 0.58–1.31 0.510
Post-progression survival
Age 1.01 0.99–1.03 0.461
No therapy for recurrent disease* 4.86 2.59–9.12 <0.001
KPS at recurrent disease (<80/>/=80) 1.48 0.90–2.42 0.123
Multifocal primary tumor 1.05 0.65–1.71 0.831
Primary tumor: contact to ventricle 0.96 0.56–1.65 0.874
Multifocal recurrence 1.42 0.84–2.41 0.193
Recurrence: contact to ventricle* 1.85 1.04–3.28 0.036
Ependymal spread* 2.97 1.41–6.26 0.004
Recurrence location (distant vs. local)* 1.75 1.10–2.79 0.019
Table 4. Multivariate survival analysis (Cox regression model) CI: Confidence interval; *P < 0.05.
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RANO criteria for tumor progression in this study19. Besides this, tumor recurrence was proven histopathologi-
cally in almost half of the patients and by advanced imaging methods in 23 cases.
Conclusions
Postoperative infarct volume is associated with recurrence patterns (multifocal, contact to ventricle/dura) which 
might be an explanation for the impaired overall survival of patients with large postoperative infarctions. A pos-
sible pathomechanism might be hypoxia-induced tumor growth. Further studies investigating this relationship 
might have to be performed to find therapy regimes for this aggressive tumor type with poor prognosis.
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